Jasper Pharmaceuticals completed its merger with Kira Pharmaceuticals following an investment structure that included $132 million of syndicate funding. The combined organization will retain the Jasper name, with CEO and CFO roles staying with Jasper executives, and will bring together prioritized hematology and immunology programs previously housed across the two companies. The transaction follows Jasper’s earlier announcement that it was exploring strategic alternatives about six weeks prior, and was described as a merger plus concurrent private placement to accelerate development using fresh cash. The deal consolidates assets rather than simply combining pipelines, with two programs identified as coming from Kira and one from Jasper. For investors and competitors, the timing suggests continued focus on management execution and clinical differentiation as a key gating factor for large financings. In a barbell-style market, the Jasper-Kira combination reflects how companies are attempting to maximize runway and trial momentum while streamlining decision-making under one corporate umbrella.